These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30422819)

  • 1. In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia.
    Wang H; Georgakopoulou A; Psatha N; Li C; Capsali C; Samal HB; Anagnostopoulos A; Ehrhardt A; Izsvák Z; Papayannopoulou T; Yannaki E; Lieber A
    J Clin Invest; 2019 Feb; 129(2):598-615. PubMed ID: 30422819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements.
    Wang H; Georgakopoulou A; Li C; Liu Z; Gil S; Bashyam A; Yannaki E; Anagnostopoulos A; Pande A; Izsvák Z; Papayannopoulou T; Lieber A
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
    Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
    Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors.
    Li C; Mishra AS; Gil S; Wang M; Georgakopoulou A; Papayannopoulou T; Hawkins RD; Lieber A
    Mol Ther; 2019 Dec; 27(12):2195-2212. PubMed ID: 31494053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.
    Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA
    Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.
    Li C; Wang H; Georgakopoulou A; Gil S; Yannaki E; Lieber A
    Mol Ther; 2021 Feb; 29(2):822-837. PubMed ID: 32949495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
    Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
    Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors.
    Richter M; Saydaminova K; Yumul R; Krishnan R; Liu J; Nagy EE; Singh M; Izsvák Z; Cattaneo R; Uckert W; Palmer D; Ng P; Haworth KG; Kiem HP; Ehrhardt A; Papayannopoulou T; Lieber A
    Blood; 2016 Nov; 128(18):2206-2217. PubMed ID: 27554082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy for beta-thalassemia.
    Malik P; Arumugam PI
    Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.
    Persons DA; Hargrove PW; Allay ER; Hanawa H; Nienhuis AW
    Blood; 2003 Mar; 101(6):2175-83. PubMed ID: 12411297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies.
    Li C; Psatha N; Wang H; Singh M; Samal HB; Zhang W; Ehrhardt A; Izsvák Z; Papayannopoulou T; Lieber A
    Mol Ther Methods Clin Dev; 2018 Jun; 9():142-152. PubMed ID: 29766024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of FV vectors with human α- or β-globin gene regulatory elements for the correction of β-thalassemia.
    Morianos I; Siapati EK; Pongas G; Vassilopoulos G
    Gene Ther; 2012 Mar; 19(3):303-11. PubMed ID: 21734726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
    Persons DA; Allay ER; Sawai N; Hargrove PW; Brent TP; Hanawa H; Nienhuis AW; Sorrentino BP
    Blood; 2003 Jul; 102(2):506-13. PubMed ID: 12663444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.
    Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR
    Gene; 2022 Apr; 820():146289. PubMed ID: 35143940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.
    Imren S; Payen E; Westerman KA; Pawliuk R; Fabry ME; Eaves CJ; Cavilla B; Wadsworth LD; Beuzard Y; Bouhassira EE; Russell R; London IM; Nagel RL; Leboulch P; Humphries RK
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14380-5. PubMed ID: 12391330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy.
    Persons DA; Allay ER; Sabatino DE; Kelly P; Bodine DM; Nienhuis AW
    Blood; 2001 May; 97(10):3275-82. PubMed ID: 11342459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic therapy for beta-thalassemia: from the bench to the bedside.
    Arumugam P; Malik P
    Hematology Am Soc Hematol Educ Program; 2010; 2010():445-50. PubMed ID: 21239833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice.
    Tan M; Qing K; Zhou S; Yoder MC; Srivastava A
    Mol Ther; 2001 Jun; 3(6):940-6. PubMed ID: 11407908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells.
    Papanikolaou E; Georgomanoli M; Stamateris E; Panetsos F; Karagiorga M; Tsaftaridis P; Graphakos S; Anagnou NP
    Hum Gene Ther; 2012 Jan; 23(1):15-31. PubMed ID: 21875313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy.
    Li W; Xie S; Guo X; Gong X; Wang S; Lin D; Zhang J; Ren Z; Huang S; Zeng F; Zeng Y
    Haematologica; 2008 Mar; 93(3):356-62. PubMed ID: 18268280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.